Key regions: Brazil, India, Australia, United States, United Kingdom
The Antiviral Drugs market in Africa has been experiencing growth in recent years, driven by various factors such as increasing prevalence of viral diseases, rising awareness about the importance of early diagnosis and treatment, and growing investment in healthcare infrastructure.
Customer preferences: Customers in the African market tend to prefer affordable and accessible antiviral drugs that are effective in treating a wide range of viral diseases. Due to the high prevalence of HIV/AIDS in the region, antiretroviral drugs are in high demand, with a preference for combination therapies that can effectively suppress the virus and improve the quality of life for patients.
Trends in the market: One of the key trends in the African antiviral drugs market is the increasing use of generic drugs, which are more affordable and accessible than branded drugs. This has been driven by the growing number of local manufacturers who are producing high-quality generic drugs that are approved by regulatory authorities. Another trend is the growing focus on research and development of new antiviral drugs that are more effective and have fewer side effects.
Local special circumstances: The African antiviral drugs market is characterized by significant regional variations in disease prevalence, healthcare infrastructure, and regulatory frameworks. For example, countries in Southern Africa have a higher prevalence of HIV/AIDS compared to other regions, which has led to a greater demand for antiretroviral drugs. In addition, some countries have limited healthcare infrastructure, which can affect the availability and accessibility of antiviral drugs.
Underlying macroeconomic factors: The African antiviral drugs market is influenced by various macroeconomic factors such as population growth, urbanization, and government healthcare spending. With a growing population and increasing urbanization, there is a greater demand for healthcare services, including antiviral drugs. In addition, many African governments are investing in healthcare infrastructure and increasing healthcare spending, which is expected to drive growth in the antiviral drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
